tiprankstipranks
CalciMedica (CALC)
NASDAQ:CALC
US Market

CalciMedica (CALC) Income Statement

236 Followers

CalciMedica Income Statement

Last quarter (Q1 2024), CalciMedica's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, CalciMedica's net income was $130.00K. See CalciMedica’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 21.58M$ 38.10M$ 36.18M$ 35.95M$ 29.83M$ 37.50M
Operating Income
$ -21.50M$ -38.08M$ -36.18M$ -35.95M$ -29.83M$ -37.50M
Net Non Operating Interest Income Expense
--$ 575.00K$ 126.00K$ 143.00K$ 393.00K
Other Income Expense
$ -1.08M$ -660.00K$ 1.31M-$ 2.16M$ 72.00K
Pretax Income
$ -14.94M$ -34.36M$ -35.60M$ -35.82M$ -27.53M$ -37.04M
Tax Provision
$ 1.00K$ 1.00K----
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -14.94M$ -34.36M$ -35.60M$ -35.82M$ -34.72M$ -37.04M
Basic EPS
$ 15.78$ -7.66$ -1.66$ 0.00$ -5.25$ -3.09
Diluted EPS
$ 15.78$ -7.66$ -1.66$ -23.66$ -5.25$ -3.09
Basic Average Shares
$ 26.88M$ 4.49M$ 21.49M$ 1.51M$ 6.62M$ 12.00M
Diluted Average Shares
$ 27.17M$ 4.49M$ 21.49M$ 1.51M$ 6.62M$ 12.00M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 21.58M$ 38.10M$ 36.18M$ 35.95M$ 29.83M$ 37.50M
Net Income From Continuing And Discontinued Operation
$ -14.94M$ -34.36M$ -35.60M$ -35.82M$ -27.53M$ -37.04M
Normalized Income
$ -8.63M---$ -27.53M$ -37.04M
Interest Expense
------
EBIT
$ -17.39M$ -34.25M$ -35.60M$ -35.95M$ -29.83M$ -37.50M
EBITDA
$ -17.39M$ -34.19M$ -35.35M$ -35.39M$ -29.44M$ -37.20M
Currency in USD

CalciMedica Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis